Rucha Patil, PhD, ICMR-National Institute of Immunohematology, Mumbai, India, highlights promising antibodies being explored in hemophilia treatment, including emicizumab and concizumab. Dr Patil also comments on a novel diagnostic tool being developed for patients with bleeding disorders. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.